Dicyclomine
Bentyl (dicyclomine) is a small molecule pharmaceutical. Dicyclomine was first approved as Dicyclomine hydrochloride on 1982-01-01. It is used to treat irritable bowel syndrome in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2 and muscarinic acetylcholine receptor M4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Bentyl (generic drugs available since 1982-01-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bentyl | New Drug Application | 2023-02-04 |
| dicyclomine hydrochloride | ANDA | 2023-06-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| irritable bowel syndrome | EFO_0000555 | D043183 | K58 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0500 | Injection, dicyclomine hcl, up to 20 mg |
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endocarditis | D004696 | EFO_0000465 | I33 | — | — | — | 2 | — | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | — | — | — | 1 | — | 1 |
| Infectious arthritis | D001170 | EFO_1001351 | M00 | — | — | — | 1 | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | 1 | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Drug interactions | D004347 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DICYCLOMINE |
| INN | dicycloverine |
| Description | Dicyclomine is the ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome. It has a role as a muscarinic antagonist, an antispasmodic drug and a parasympatholytic. It is a tertiary amine and a carboxylic ester. It is functionally related to a 2-diethylaminoethanol and a 1,1'-bi(cyclohexyl)-1-carboxylic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 77-19-0 |
| RxCUI | 3361 |
| ChEMBL ID | CHEMBL1123 |
| ChEBI ID | 4514 |
| PubChem CID | 3042 |
| DrugBank | DB00804 |
| UNII ID | 4KV4X8IF6V (ChemIDplus, GSRS) |
Target
Alternate
CHRM2
CHRM2
CHRM4
CHRM4
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 977 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
307 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more